The obesity drug’s new formulation gains an important opportunity to define the market before regulators finish assessing Lilly’s rival orforglipron.
Novo Nordisk’s Wegovy (semaglutide) has become the first oral glucagon-like peptide 1 (GLP-1) receptor agonist to be available in the US for weight management.